Antineoplastic Agents, Immunological

Preferred Label : Antineoplastic Agents, Immunological;

Obsolete resource : false;

MeSH definition : Antineoplastic agents containing immunological agents (e.g. MAbs). These pharmacologic preparations inhibit or prevent the proliferation of NEOPLASMS.;

MeSH synonym : Immunological Antineoplastic Agents;

MeSH hyponym : Antibodies Antineoplastics, Monoclonal; Monoclonal Antibodies Antineoplastics; Monoclonal Antibodies, Antineoplastic; Antineoplastic Monoclonal Antibodies; Antineoplastic MAbs; Antineoplastics, Monoclonal Antibody; Monoclonal Antibody Antineoplastics; MAbs, Antineoplastic;

Details

Origin ID

D000074322;

UMLS CUI

C4505220;

Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- analysis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Metaterm(s)
- allergy and immunology [CISMeF Metaterm]
Record concept(s)
- Antineoplastic Agents, Immunological [MeSH concept]
- Antineoplastics, Monoclonal Antibodies [MeSH concept]
See also (suggested by CISMeF)
- immunologic factors [MeSH Descriptor]
Semantic type(s)
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
Substance(s)
- Ado-Trastuzumab Emtansine [MeSH Descriptor]
- Alemtuzumab [MeSH Descriptor]
- BI 836826 [MeSH Supplementary Concept]
- BMS-936559 [MeSH Supplementary Concept]
- Bevacizumab [MeSH Descriptor]
- Brentuximab Vedotin [MeSH Descriptor]
- Cetuximab [MeSH Descriptor]
- DS-8273a [MeSH Supplementary Concept]
- Gemtuzumab [MeSH Descriptor]
- Inotuzumab Ozogamicin [MeSH Descriptor]
- Nivolumab [MeSH Descriptor]
- PF-06263507 [MeSH Supplementary Concept]
- Panitumumab [MeSH Descriptor]
- Rituximab [MeSH Descriptor]
- Trastuzumab [MeSH Descriptor]
- U3-1565 [MeSH Supplementary Concept]
- abagovomab [MeSH Supplementary Concept]
- amivantamab-vmjw [MeSH Supplementary Concept]
- avelumab [MeSH Supplementary Concept]
- axicabtagene ciloleucel [MeSH Supplementary Concept]
- bavituximab [MeSH Supplementary Concept]
- bemarituzumab [MeSH Supplementary Concept]
- bivatuzumab mertansine [MeSH Supplementary Concept]
- brexucabtagene autoleucel [MeSH Supplementary Concept]
- cantuzumab mertansine [MeSH Supplementary Concept]
- cemiplimab [MeSH Supplementary Concept]
- conatumumab [MeSH Supplementary Concept]
- dacetuzumab [MeSH Supplementary Concept]
- durvalumab [MeSH Supplementary Concept]
- ecromeximab [MeSH Supplementary Concept]
- epratuzumab [MeSH Supplementary Concept]
- glembatumumab vedotin [MeSH Supplementary Concept]
- idecabtagene vicleucel [MeSH Supplementary Concept]
- intetumumab [MeSH Supplementary Concept]
- labetuzumab [MeSH Supplementary Concept]
- lintuzumab [MeSH Supplementary Concept]
- loncastuximab tesirine [MeSH Supplementary Concept]
- lorvotuzumab mertansine [MeSH Supplementary Concept]
- magrolimab [MeSH Supplementary Concept]
- necitumumab [MeSH Supplementary Concept]
- nimotuzumab [MeSH Supplementary Concept]
- obinutuzumab [MeSH Supplementary Concept]
- oregovomab [MeSH Supplementary Concept]
- patritumab deruxtecan [MeSH Supplementary Concept]
- pembrolizumab [MeSH Supplementary Concept]
- pertuzumab [MeSH Supplementary Concept]
- pidilizumab [MeSH Supplementary Concept]
- rilotumumab [MeSH Supplementary Concept]
- rindopepimut [MeSH Supplementary Concept]
- talimogene laherparepvec [MeSH Supplementary Concept]
- tisagenlecleucel [MeSH Supplementary Concept]
- tislelizumab [MeSH Supplementary Concept]
- tisotumab vedotin [MeSH Supplementary Concept]
- zalutumumab [MeSH Supplementary Concept]
- zanolimumab [MeSH Supplementary Concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients